Recursion Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US75629V1044

SecurityRXRX / Recursion Pharmaceuticals, Inc.
InstitutionCitigroup Inc
Latest Disclosed Ownership182,610 shares
Latest Disclosed Value $ 560,612
Citigroup Inc ownership in RXRX / Recursion Pharmaceuticals, Inc.

On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 182,610 shares of Recursion Pharmaceuticals, Inc. (US:RXRX) valued at $560,613 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 170,287 shares of Recursion Pharmaceuticals, Inc.. This represents a change in shares of 7.24% during the quarter. The current value of the position is $633,657 USD.

Citigroup Inc has a history of taking positions in derivatives of the underlying security (RXRX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

RXRX / Recursion Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 182,610 12,323 7.24 561 -19.54 0.0001
2026-02-13 2025-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 170,287 103,886 156.45 696 114.81 0.0003
2025-11-10 2025-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 66,401 -148,346 -69.08 324 -70.17 0.0001
2025-08-11 2025-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 214,747 -444,702 -67.44 1,087 -68.86 0.0005
2025-05-12 2025-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 659,449 158,461 31.63 3,488 3.01 0.0018
2025-02-12 2024-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 500,988 310,236 162.64 3,387 169.37 0.0020
2024-11-12 2024-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 190,752 87,142 84.11 1,257 61.78 0.0007
2024-08-12 2024-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 103,610 -697,577 -87.07 777 -90.27 0.0005
2024-05-10 2024-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 801,187 396,334 97.90 7,988 100.13 0.0052
2024-02-09 2023-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 404,853 -65,659 -13.95 3,992 10.89 0.0028
2023-12-06 2023-09-30 13F/A-1 RECURSION PHARMACEUTICALS IN CL A 75629V104 470,512 293,174 165.32 3,599 171.83 0.0027
2023-11-09 2023-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 470,512 293,174 3,599 0.0027
2023-08-10 2023-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 177,338 -510,887 -74.23 1,325 -71.15 0.0009
2023-05-11 2023-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 688,225 455,398 195.60 4,590 155.71 0.0032
2023-02-09 2022-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 232,827 71,267 44.11 1,795 4.42 0.0014
2022-11-10 2022-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 161,560 149,260 1,213.50 1,719 1,619.00 0.0012
2022-08-10 2022-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 12,300 -2,599 -17.44 100 -5.66 0.0001
2022-05-12 2022-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 14,899 -229,458 -93.90 106 -97.47 0.0001
2022-02-10 2021-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 244,357 199,063 439.49 4,186 301.73 0.0022
2021-11-10 2021-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 45,294 44,288 4,402.39 1,042 2,716.22 0.0006
2021-08-10 2021-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 1,006 1,006 37 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-11 2026-03-31 13F RECURSION PHARMACEUTICALS IN CL A Call 0 -100.00 0 -100.00 n/a n/a n/a
2026-02-13 2025-12-31 13F RECURSION PHARMACEUTICALS IN CL A Call 30,000 123 n/a n/a n/a
2025-05-12 2025-03-31 13F RECURSION PHARMACEUTICALS IN CL A Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-02-12 2024-12-31 13F RECURSION PHARMACEUTICALS IN CL A Call 22,100 149 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-11 2026-03-31 13F RECURSION PHARMACEUTICALS IN CL A Put 0 -100.00 0 -100.00 n/a n/a n/a
2026-02-13 2025-12-31 13F RECURSION PHARMACEUTICALS IN CL A Put 30,000 123 n/a n/a n/a
2025-05-12 2025-03-31 13F RECURSION PHARMACEUTICALS IN CL A Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-02-12 2024-12-31 13F RECURSION PHARMACEUTICALS IN CL A Put 22,100 149 n/a n/a n/a
2024-08-12 2024-06-30 13F RECURSION PHARMACEUTICALS IN CL A Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-05-10 2024-03-31 13F RECURSION PHARMACEUTICALS IN CL A Put 62,700 625 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.